MCAS and Histamine Intolerance
Histamine intolerance and Mast Cell Activation Syndrome (MCAS) are two distinct but overlapping conditions which are on the rise. They involve the release and response to histamine in the body.
Histamine intolerance is primarily characterized by the body's inability to properly metabolize and break down histamine. This leads to an accumulation of histamine in the body, which can result in symptoms when histamine-rich foods are consumed.
MCAS is a debilitating condition in which mast cells, a type of immune cell, are thought to become overactive and release excessive amounts of histamine and other inflammatory compounds. This can lead to systemic and chronic symptoms throughout the body. MCAS is often considered a systemic disorder of mast cells, where the mast cells themselves are dysfunctional or overly sensitive. It is characterized by an abnormal response of mast cells to various triggers, including stress, infections, and environmental factors.
In essence, both histamine intolerance and MCAS share a common issue: the body's struggle to efficiently break down histamine at the same rate it's produced. While histamine is essential for digestion and overall bodily functions, symptoms arise when its clearance falls behind. Emerging research points to a potential link between these conditions and deficiencies in functional B2 and B12 vitamins.
References
Afrin, L.B., Ackerley, M.B., Bluestein, L.S., Brewer, J.H., Brook, J.B., Buchanan, A.D., Cuni, J.R., Davey, W.P., Dempsey, T.T., Dorff, S.R. and Dubravec, M.S., 2021. Diagnosis of mast cell activation syndrome: a global "consensus-2". Diagnosis, 8(2), pp.137-152.
Comas-Basté, O., Sánchez-Pérez, S., Veciana-Nogués, M.T., Latorre-Moratalla, M. and Vidal-Carou, M.D.C., 2020. Histamine intolerance: The current state of the art. Biomolecules, 10(8), p.1181.
Frieri, M., Patel, R. and Celestin, J., 2013. Mast cell activation syndrome: a review. Current allergy and asthma reports, 13, pp.27-32.
Hrubisko, M., Danis, R., Huorka, M. and Wawruch, M., 2021. Histamine Intolerance—The More We Know the Less We Know. A Review. Nutrients, 13(7), p.2228.
Maintz, L. and Novak, N., 2007. Histamine and histamine intolerance. The American journal of clinical nutrition, 85(5), pp.1185-1196.
Russell-Jones, G (n.d.). MCAS & Histamine Intolerance - Is B12 Oil a Solution? B12 Oils. Available at: https://b12oils.com/mcas.htm Accessed 13 November 2023.
Sánchez-Pérez, S., Comas-Basté, O., Duelo, A., Veciana-Nogués, M.T., Berlanga, M., Latorre-Moratalla, M.L. and Vidal-Carou, M.C., 2022. Intestinal dysbiosis in patients with histamine intolerance. Nutrients, 14(9), p.1774.
Schnedl, W.J. and Enko, D., 2021. Histamine intolerance originates in the gut. Nutrients, 13(4), p.1262.
Tan, Z., Ou, Y., Cai, W., Zheng, Y., Li, H., Mao, Y., Zhou, S. and Tu, J., 2022. Advances in the Clinical Application of Histamine and Diamine Oxidase (DAO) Activity: A Review. Catalysts, 13(1), p.48.
Thakur, K., Tomar, S.K., Singh, A.K., Mandal, S. and Arora, S., 2017. Riboflavin and health: A review of recent human research. Critical reviews in food science and nutrition, 57(17), pp.3650-3660.
Valent, P. and Akin, C., 2019. Doctor, I think I am suffering from MCAS: differential diagnosis and separating facts from fiction. The Journal of Allergy and Clinical Immunology: In Practice, 7(4), pp.1109-1114.
Valent, P., Akin, C., Nedoszytko, B., Bonadonna, P., Hartmann, K., Niedoszytko, M., Brockow, K., Siebenhaar, F., Triggiani, M., Arock, M. and Romantowski, J., 2020. Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine. International journal of molecular sciences, 21(23), p.9030.
Zhao, Y., Zhang, X., Jin, H., Chen, L., Ji, J. and Zhang, Z., 2022. Histamine intolerance—a kind of pseudoallergic reaction. Biomolecules, 12(3), p.454.